Teva Pharmaceutical Industries
TEVA
39.18
+0.05
+0.13%
Teva Pharmaceutical Industries
US · TEVA
#471 by market cap
Listed 1970
39.18
+0.05
+0.13%
Live - 5344 symbols - heartbeat 152s ago
· 2026-10-08 08:25
Pre-market
38.81
-0.94%
After-hours
39.18
0.00%
Overnight
38.80
-0.97%
- Market cap
- 45.70B
- P/E (TTM)i
- 65.30
- P/Bi
- 5.89
- EPSi
- 1.21
- Div yieldi
- 0.00%
- 52W posi
- 93%
Reader sentiment
Are you bullish or bearish on TEVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.12, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.32% YoY
Margins
- Gross margin
- 51.79%
- Operating margin
- 22.90%
- Net margin
- 8.17%
Key ratios & quality
- Enterprise valuei
- 58.95B
- Altman Z-Scorei
- 1.12
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.27B | 16.89B | 16.66B | 15.88B | 14.93B | 15.85B | 16.54B | 17.26B |
| Gross profit | 8.30B | 7.54B | 7.73B | 7.59B | 6.97B | 7.65B | 8.06B | 8.94B |
| Selling & admin expenses | 4.21B | 3.81B | 3.67B | 3.53B | 3.45B | 3.50B | 3.70B | 3.97B |
| Research & development | 1.21B | 1.01B | 997.00M | 967.00M | 838.00M | 953.00M | 998.00M | 1.01B |
| Operating profit | 2.87B | 2.72B | 3.06B | 3.10B | 2.69B | 3.19B | 3.36B | 3.95B |
| Pretax profit | -2.60B | -1.27B | -4.41B | 658.00M | -3.16B | -624.00M | -1.28B | 1.22B |
| Tax | -195.00M | -278.00M | -168.00M | 211.00M | -643.00M | -7.00M | 676.00M | -180.00M |
| Net profit | -2.47B | -1.00B | -4.10B | 456.00M | -2.50B | -615.00M | -1.96B | 1.42B |
| Basic EPS | -2 | -1 | -4 | 0 | -2 | -1 | -1 | 1 |
| Diluted EPS | -2.35 | -0.91 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.89B | 4.18B | 4.48B | 4.71B | 3.98B | 4.14B |
| Gross profit | 1.88B | 2.10B | 2.30B | 2.66B | 1.97B | 2.15B |
| Selling & admin expenses | 919.00M | 959.00M | 973.00M | 1.12B | 1.00B | 1.03B |
| Research & development | 247.00M | 244.00M | 256.00M | 267.00M | 222.00M | 970.00M |
| Operating profit | 706.00M | 899.00M | 1.08B | 1.27B | 759.00M | 149.00M |
| Pretax profit | 294.00M | 203.00M | 646.00M | 80.00M | 437.00M | -455.00M |
| Tax | 74.00M | -78.00M | 214.00M | -390.00M | 67.00M | 121.00M |
| Net profit | 220.00M | 283.00M | 434.00M | 481.00M | 369.00M | -575.00M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.18 | 0.24 | 0.37 | 0.41 | 0.31 | -0.49 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 13.79B | 13.46B | 13.01B | 12.57B | 12.05B | 12.49B | 12.55B | 13.95B |
| Cash & ST investments | 1.78B | 1.98B | 2.18B | 2.17B | 2.80B | 3.23B | 3.30B | 3.56B |
| Inventory | 4.73B | 4.42B | 4.40B | 3.82B | 3.83B | 4.02B | 3.01B | 3.18B |
| Total assets | 60.68B | 57.47B | 50.64B | 47.67B | 44.01B | 43.48B | 39.33B | 40.75B |
| Total current liabilities | 14.32B | 13.67B | 13.16B | 11.03B | 11.47B | 12.25B | 12.80B | 13.46B |
| Short-term debt | 2.22B | 2.35B | 3.19B | 1.43B | 2.11B | 1.67B | 1.78B | 1.82B |
| Long-term debt | 26.70B | 24.56B | 22.73B | 21.62B | 19.10B | 18.16B | 16.00B | 14.99B |
| Total liabilities | 44,889,000,000.00 | 42,407,000,000.00 | 39,579,000,000.00 | 36,422,000,000.00 | 35,413,000,000.00 | 35,353,000,000.00 | 33,606,000,000.00 | 32,834,000,000.00 |
| Total equity | 15.79B | 15.06B | 11.06B | 11.24B | 8.60B | 8.13B | 5.72B | 7.91B |
| Retained earnings | -5.96B | -6.96B | -10.95B | -10.53B | -12.98B | -13.53B | -15.17B | -13.76B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 11.53B | 12.62B | 12.74B | 13.95B | 13.71B | 13.76B |
| Cash & ST investments | 1.70B | 2.16B | 2.20B | 3.56B | 3.74B | 3.66B |
| Inventory | 3.25B | 3.50B | 3.32B | 3.18B | 3.18B | 3.22B |
| Total assets | 38.42B | 40.13B | 39.86B | 40.75B | 40.04B | 39.86B |
| Total current liabilities | 11.16B | 11.86B | 11.49B | 13.46B | 13.53B | 15.65B |
| Short-term debt | 421.00M | 464.00M | 24.00M | 1.82B | 2.61B | 4.50B |
| Long-term debt | 16.23B | 16.76B | 16.77B | 14.99B | 14.02B | 12.09B |
| Total liabilities | 32,146,000,000.00 | 33,297,000,000.00 | 32,602,000,000.00 | 32,834,000,000.00 | 31,808,000,000.00 | 32,100,000,000.00 |
| Total equity | 6.27B | 6.83B | 7.25B | 7.91B | 8.23B | 7.76B |
| Retained earnings | -14.96B | -14.68B | -14.24B | -13.76B | -13.39B | -13.97B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.45B | 748.00M | 1.22B | 798.00M | 1.59B | 1.37B | 1.25B | 1.65B |
| Depreciation & amortization | 1.84B | 1.72B | 1.56B | 1.33B | 1.31B | 1.15B | 1.06B | 1.00B |
| Free cash flow | 1.80B | 223.00M | 638.00M | 236.00M | 1.04B | 842.00M | 749.00M | 1.15B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.78B | 1.98B | 2.18B | 2.20B | 2.83B | 3.23B | 3.30B | 3.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -105.00M | 227.00M | 369.00M | 1.16B | -40.00M | 411.00M |
| Depreciation & amortization | 244.00M | 251.00M | 249.00M | 260.00M | 239.00M | 241.00M |
| Free cash flow | -232.00M | 131.00M | 233.00M | 1.02B | -208.00M | 307.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.70B | 2.16B | 2.20B | 3.56B | 3.74B | 3.66B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -16.87 | -6.97 | -33.25 | 4.11 | -25.89 | -7.26 | -25.45 | 21.23 |
| ROA %i | -3.65 | -1.69 | -7.38 | 0.85 | -5.13 | -1.28 | -3.96 | 3.52 |
| ROIC %i | -3.46 | -0.73 | -7.89 | 3.31 | -5.12 | 1.61 | -3.39 | 8.73 |
| 5-year avg ROE %i | -14.61 | -18.67 | -26.58 | -25.81 | -16.01 | -14.09 | -17.79 | -6.89 |
| EBIT margin %i | -8.89 | -2.27 | -20.67 | 9.76 | -14.30 | 2.56 | -1.70 | 12.40 |
| FCF / sales %i | 9.52 | 1.32 | 3.83 | 1.49 | 6.98 | 5.31 | 4.53 | 6.65 |
| Current ratioi | 0.96 | 0.98 | 0.99 | 1.14 | 1.05 | 1.02 | 0.98 | 1.04 |
| Quick ratioi | 0.53 | 0.56 | 0.51 | 0.61 | 0.57 | 0.54 | 0.50 | 0.54 |
| Debt / assetsi | 47.65 | 47.58 | 52.13 | 49.22 | 48.99 | 46.35 | 45.97 | 41.95 |
| LT debt / equityi | 181.55 | 178.91 | 231.50 | 214.37 | 249.26 | 246.22 | 303.33 | 193.10 |
| Interest coveragei | -1.82 | -0.44 | -3.58 | 1.74 | -2.30 | 0.39 | -0.28 | 2.34 |
| Revenue CAGR (3Y) %i | -2.40 | -8.30 | -8.65 | -4.57 | -4.03 | -1.65 | 1.38 | 4.96 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -27.80 | -57.90 | -22.13 | -49.15 | 67.18 | 9.69 | 46.96 | 3.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -19.00 | -2.38 | 10.71 | 21.23 | 21.60 | 9.68 |
| ROA %i | -3.17 | -0.39 | 1.75 | 3.52 | 3.99 | 1.77 |
| ROIC %i | -2.12 | 2.32 | 5.64 | 8.73 | 9.36 | 6.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.73 | 5.27 | 10.92 | 12.40 | 13.09 | 9.27 |
| FCF / sales %i | 4.60 | 5.35 | 3.45 | 6.65 | 6.76 | 7.78 |
| Current ratioi | 1.03 | 1.06 | 1.11 | 1.04 | 1.01 | 0.88 |
| Quick ratioi | 0.46 | 0.48 | 0.52 | 0.54 | 0.53 | 0.46 |
| Debt / assetsi | 44.09 | 43.66 | 42.84 | 41.95 | 42.23 | 42.34 |
| LT debt / equityi | 263.78 | 249.88 | 235.16 | 193.10 | 173.74 | 159.60 |
| Interest coveragei | 0.46 | 0.92 | 1.96 | 2.34 | 2.51 | 1.79 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Generic products (including OTC and biosimilars) is the largest reported line at 59.81% of revenue, across 8 reported segments.
- AUSTEDO follows at 19.80%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Generic products (including OTC and biosimilars)59.81%
AUSTEDO19.80%
AJOVY ®6.91%
Other5.49%
COPAXONE3.36%
UZEDY2.19%
Respiratory products1.65%
BENDEKA ® and TREANDA ®0.80%
Quote time 2026-10-08 08:25:10 · For reference only, not investment advice and not tailored to your situation.